MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer
- DOI
- 10.1186/s13058-020-01318-2
- Published
- 2020-08-12
- Container
- Breast Cancer Research
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1186/s13058-020-01318-2,
title = {MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer},
author = {Neil Portman and Heloisa H. Milioli and Sarah Alexandrou and Rhiannon Coulson and Aliza Yong and Kristine J. Fernandez and Kee Ming Chia and Ensar Halilovic and Davendra Segara and Andrew Parker and Sue Haupt and Ygal Haupt and Wayne D. Tilley and Alex Swarbrick and C. Elizabeth Caldon and Elgene Lim},
year = {2020},
journal = {Breast Cancer Research},
doi = {10.1186/s13058-020-01318-2},
url = {https://doi.org/10.1186/s13058-020-01318-2}
}RIS
TY - JOUR TI - MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer AU - Neil Portman AU - Heloisa H. Milioli AU - Sarah Alexandrou AU - Rhiannon Coulson AU - Aliza Yong AU - Kristine J. Fernandez AU - Kee Ming Chia AU - Ensar Halilovic AU - Davendra Segara AU - Andrew Parker AU - Sue Haupt AU - Ygal Haupt AU - Wayne D. Tilley AU - Alex Swarbrick AU - C. Elizabeth Caldon AU - Elgene Lim PY - 2020 JO - Breast Cancer Research DO - 10.1186/s13058-020-01318-2 UR - https://doi.org/10.1186/s13058-020-01318-2 ER -
APA
Portman, N., Milioli, H. H., Alexandrou, S., Coulson, R., Yong, A., Fernandez, K. J., Chia, K. M., Halilovic, E., Segara, D., Parker, A., Haupt, S., Haupt, Y., Tilley, W. D., Swarbrick, A., Caldon, C. E., & Lim, E. (2020). MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer. Breast Cancer Research. https://doi.org/10.1186/s13058-020-01318-2
Source records
- crossref · retrieved 2026-09-26T02:42:10.941Z